198 related articles for article (PubMed ID: 28294075)
1. β -[
Kumar P; Roselt P; Reischl G; Cullinane C; Beiki D; Ehrlichmann W; Binns D; Naimi E; Yang J; Hicks R; Machulla HJ; Wiebe LI
Curr Radiopharm; 2017; 10(2):93-101. PubMed ID: 28294075
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of [
Sun W; Falzon C; Naimi E; Akbari A; Wiebe LI; Tandon M; Kumar P
Curr Radiopharm; 2019; 12(1):49-57. PubMed ID: 30338747
[TBL] [Abstract][Full Text] [Related]
3. [
Schweifer A; Maier F; Ehrlichmann W; Lamparter D; Kneilling M; Pichler BJ; Hammerschmidt F; Reischl G
Nucl Med Biol; 2016 Dec; 43(12):759-769. PubMed ID: 27693670
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of hypoxia imaging agent 1-(5-deoxy-5-fluoro-α-D-arabinofuranosyl)-2-nitroimidazole using microfluidic technology.
Bouvet VR; Wuest M; Wiebe LI; Wuest F
Nucl Med Biol; 2011 Feb; 38(2):235-45. PubMed ID: 21315279
[TBL] [Abstract][Full Text] [Related]
5. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA).
Postema EJ; McEwan AJ; Riauka TA; Kumar P; Richmond DA; Abrams DN; Wiebe LI
Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1565-73. PubMed ID: 19430784
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Bioevaluation of Novel [
Yang X; Wang F; Zhu H; Yang Z; Chu T
Mol Pharm; 2019 May; 16(5):2118-2128. PubMed ID: 30964298
[TBL] [Abstract][Full Text] [Related]
7. Microwave-assisted radiosynthesis of the hypoxia marker 1-α-D-(5- deoxy-5-[18F]fluoroarabinofuranosyl)-2-nitroimidazole ([18F]FAZA).
Kumar P; Ortlieb R; Gupta AK; Wiebe LI
Curr Radiopharm; 2014; 7(1):49-56. PubMed ID: 25022345
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three
Dos Santos SN; Wuest M; Jans HS; Woodfield J; Nario AP; Krys D; Dufour J; Glubrecht D; Bergman C; Bernardes ES; Wuest F
Nucl Med Biol; 2023; 124-125():108383. PubMed ID: 37651917
[TBL] [Abstract][Full Text] [Related]
9. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.
Reischl G; Dorow DS; Cullinane C; Katsifis A; Roselt P; Binns D; Hicks RJ
J Pharm Pharm Sci; 2007; 10(2):203-11. PubMed ID: 17706178
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
Piert M; Machulla HJ; Picchio M; Reischl G; Ziegler S; Kumar P; Wester HJ; Beck R; McEwan AJ; Wiebe LI; Schwaiger M
J Nucl Med; 2005 Jan; 46(1):106-13. PubMed ID: 15632040
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and preclinical characterization of 1-(6'-deoxy-6'-[
Wanek T; Kreis K; Križková P; Schweifer A; Denk C; Stanek J; Mairinger S; Filip T; Sauberer M; Edelhofer P; Traxl A; Muchitsch VE; Mereiter K; Hammerschmidt F; Cass CE; Damaraju VL; Langer O; Kuntner C
Bioorg Med Chem; 2016 Nov; 24(21):5326-5339. PubMed ID: 27614920
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, radiofluorination, and hypoxia-selective studies of FRAZ: A configurational and positional analogue of the clinical hypoxia marker, [18F]-FAZA.
Kumar P; Naimi E; McEwan AJ; Wiebe LI
Bioorg Med Chem; 2010 Mar; 18(6):2255-2264. PubMed ID: 20181485
[TBL] [Abstract][Full Text] [Related]
13. Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation.
Reischl G; Ehrlichmann W; Bieg C; Solbach C; Kumar P; Wiebe LI; Machulla HJ
Appl Radiat Isot; 2005 Jun; 62(6):897-901. PubMed ID: 15799867
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and hypoxia selective radiosensitization potential of beta-2-FAZA and beta-3-FAZL: fluorinated azomycin beta-nucleosides.
Kumar P; Emami S; Kresolek Z; Yang J; McEwan AJ; Wiebe LI
Med Chem; 2009 Mar; 5(2):118-29. PubMed ID: 19275710
[TBL] [Abstract][Full Text] [Related]
15. Positron Emission Tomography (PET) and Pharmacokinetics: Classical Blood Sampling Versus Image-Derived Analysis of [18F]FAZA and [18F]FDG in a Murine Tumor Bearing Model.
Jans HS; Yang XH; Brocks DR; Kumar P; Wuest M; Wiebe LI
J Pharm Pharm Sci; 2018; 21(1s):32s-47s. PubMed ID: 29702045
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M
J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108
[TBL] [Abstract][Full Text] [Related]
17. Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [¹⁸F]-fluoro-azomycinarabino-furanoside ([¹⁸F]FAZA).
Maier FC; Kneilling M; Reischl G; Cay F; Bukala D; Schmid A; Judenhofer MS; Röcken M; Machulla HJ; Pichler BJ
Radiat Oncol; 2011 Nov; 6():165. PubMed ID: 22118419
[TBL] [Abstract][Full Text] [Related]
18. In Vivo Ester Hydrolysis as a New Approach in Development of Positron Emission Tomography Tracers for Imaging Hypoxia.
Zhang L; Yao X; Cao J; Hong H; Zhang A; Zhao R; Zhang Y; Zha Z; Liu Y; Qiao J; Zhu L; Kung HF
Mol Pharm; 2019 Mar; 16(3):1156-1166. PubMed ID: 30676751
[TBL] [Abstract][Full Text] [Related]
19. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
Furukawa T; Yuan Q; Jin ZH; Aung W; Yoshii Y; Hasegawa S; Endo H; Inoue M; Zhang MR; Fujibayashi Y; Saga T
Oncol Rep; 2015 Sep; 34(3):1379-87. PubMed ID: 26134305
[TBL] [Abstract][Full Text] [Related]
20. 2-Nitroimidazole-Furanoside Derivatives for Hypoxia Imaging-Investigation of Nucleoside Transporter Interaction,
Maier FC; Schweifer A; Damaraju VL; Cass CE; Bowden GD; Ehrlichmann W; Kneilling M; Pichler BJ; Hammerschmidt F; Reischl G
Pharmaceuticals (Basel); 2019 Feb; 12(1):. PubMed ID: 30781409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
